# A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo

Source: [nature.com](https://www.nature.com/articles/s41587-026-03344-5) · 2026-11-16 · Life
Page: https://themorning.science/story/a-cd7-targeted-aav-variant-enables-efficient-t-and-nk-cell-engineering-in-vivo-3154916391841741
Kind: research · Impact: medium

## In brief

- A Nature Biotechnology article reports an AAV variant targeted to CD7 for engineering T and NK cells in vivo.
- The source summary states that the vector enables efficient T and NK cell engineering in vivo.

## Why it matters

It describes a way to deliver genetic engineering to T and NK cells inside the body by targeting a viral vector to CD7, which may inform the development of future cell-based therapies.

## Timeline

- 2026-11-16: Published online in Nature Biotechnology

## Coverage

- [A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo](https://www.nature.com/articles/s41587-026-03344-5) — nature.com, 2026-11-16

Tags: gene therapy, aav vectors, t cells, nk cells, in vivo engineering

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
